Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Topical corticosteroids are effective for skin conditions but can have side effects.

Teak leaf extract hair tonic was tested for hair growth and safety.

This study found that finasteride significantly promoted hair growth compared to placebo in male patients with androgenic alopecia, but also noted a high incidence of sexual side effects.

This study found that combining microneedling with PRP was more effective than microneedling alone for improving acne scars, with higher patient satisfaction and no significant increase in severe side effects.

This article provides background information on hereditary hair loss and indicates it can begin in women as early as age 30, but presents no new results.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.

No results are reported in this dataset abstract, which details supplementary materials for a systematic review and meta-analysis on oral Janus kinase inhibitors' effectiveness and safety in children with alopecia areata, aiming to enhance transparency and interpretation of the main article's findings.

In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.

This study evaluated the safety and effectiveness of HASHA, a new hyaluronic acid injectable, for chin augmentation in adults with chin retrusion. HASHA significantly improved chin appearance and satisfaction over 12 months compared to controls, with only mild or moderate transient adverse events.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

Oral retinoids can cause side effects ranging from mild to severe, including birth defects, and require careful monitoring and contraception.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

This study found that lasers and light devices may alleviate recalcitrant skin side effects in cancer patients treated with EGFR inhibitors, offering an alternative for those who do not respond to traditional therapies.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This study found that prenatal exposure to finasteride in rats led to permanent changes in developmental endpoints like anogenital distance and nipple retention, which were predictive of further reproductive tract malformations.

In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.

This paper reports on the controversy surrounding post-finasteride syndrome and questions Merck and the FDA's handling of associated sexual side effects. Despite significant adverse event reports, both entities failed to conduct further studies or enhance patient safety warnings about finasteride's long-term effects.

This commentary highlights the consistency of recent findings on low-dose oral minoxidil's tolerability for androgenetic alopecia, noting infrequent side effects except for hypertrichosis.

This case report describes a rare instance of gynecomastia in a male patient undergoing mirtazapine treatment for depression, suggesting the drug as a probable cause after ruling out other factors.

This study reported that chemotherapy-induced skin reactions in cancer patients are mostly mild to moderate and manageable with supportive care, suggesting that early dermatologic intervention can improve patient outcomes without interrupting chemotherapy.

This study developed a physician-guided algorithm to manage cutaneous adverse events from hormonal therapy in cancer patients, aiming to reduce treatment interruptions and enhance quality of life.

This article reviews the care of transgender patients, encompassing diagnosis, treatment options, and challenges in health care access, but does not present new research findings; the authors emphasize the critical role of providers in addressing transgender health needs.

This study found that 2% topical minoxidil solution was significantly more effective than placebo in promoting new hair growth in women with androgenetic alopecia.

This review examines systemic drugs that can cause changes in hair color and emphasizes the importance of reporting these adverse events, but it does not include new clinical outcomes.